[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
A 72-year-old male treated with flutamide for metastatic prostate cancer developed lethargy and confusion. He was noted to be icteric and his liver enzymes were elevated. Within a week of discontinuing the medication, the patient's mental status and liver function returned to normal. Although flutamide-induced near fatal liver dysfunction has been described, progression to encephalopathy is a rare occurrence. Based on a review of the literature, management guidelines for the use of flutamide are suggested.
Patel
H
H
Department of Urology, Kaiser Permanente, Los Angeles, California, USA.
Rhee
E
E
Zimmern
P E
PE
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000009:adverse effects* / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000139:chemically induced*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide; D016729:Leuprolide
Encéphalopathie hépatique secondaire à la prise de flutamide pour cancer de la prostate.